Moderna Inc. (MRNA) witnessed a steep pre-market decline of 21.18% on Monday, as the biotechnology company slashed its 2025 revenue forecast, citing sluggish launch of its respiratory syncytial virus (RSV) vaccine mRESVIA and waning demand for COVID-19 vaccines.
The company now expects its 2025 revenue to range between $1.5 billion and $2.5 billion, marking a significant reduction from its previous projection of $2.5 billion to $3.5 billion. This revised forecast fell short of analysts' average estimate of $2.95 billion for the year.
The disappointing outlook reflects the challenges Moderna is facing in its transition from its pandemic-driven success with COVID-19 vaccines. As the demand for these shots wanes, the company's newly launched RSV vaccine, mRESVIA, has also faced a lackluster reception, with negligible sales reported.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。